N/A N=83 Does Virtual Reality Technology Reduce Pain and Anxiety During Outpatient Hysteroscopy?
Anxiety · Pain
Primary: Reported Numeric Rating Score (NRS) Pain Score — 3.73; 4.24 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=934 Family Supportive Supervisor Training and Workplace Assessment Tool
Psychosocial Deprivation · Work-Related Stress · Life-work Imbalance
Primary: Change in Family Supportive Supervisor Behaviors — -.08; .06 units on a scale
N/A N=306 Advancing Symptom Alleviation With Palliative Treatment
Heart Failure · Pulmonary Disease, Chronic Obstructive · Emphysema
Primary: Function Assessment of Chronic Illness Therapy-General (FACT-G) — 59.0; 54.0 score on a scale
Phase 4 N=40 Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder
Primary: Changes in Blood Oxygen Level Dependent (BOLD) Signal Change on Functional MRI — 9.98; 7.67 BOLD signal change
N/A N=1,061 Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
Fatty Liver, Nonalcoholic · Diabetes Mellitus, Type 2
Primary: Action on Suspected Advanced Liver Fibrosis — 55; 4 Participants
Phase 4 N=15 Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus
Growth and Development
Primary: Number of Participants Who Achieved Tanner Stage V at or Before Age 16 (Females) or 17 (Males) — 4; 6 Participants
Phase 3 N=627 Safety of REL-1017 for Major Depressive Disorder
Major Depressive Disorder
Primary: Safety and Tolerability of REL-1017 as Incidence of Treatment Emergent Adverse Events (TEAEs) — 350 participants
Phase 2 N=192 Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial
HIV Infections
Primary: Virological Suppression at 24 Weeks — 55; 53; 53 Participants
N/A N=572 Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
Non-Small Cell Lung Cancer
Primary: Eastern Cooperative Oncology Group (ECOG) Quality of Life Score: ALK Treatment and ROS1 Sub-study Only — 35; 11; 43; 29 Participants
N/A N=50 Extracorporeal Lung Assist to Avoid Intubation in Patients Failing Noninvasive Ventilation for Hypercapnic ARF
Hypercapnia · Respiratory Insufficiency
Primary: Number of Patients With Need for Intubation for Invasive Mechanical Ventilation — 11; 25 Participants
N/A N=630 Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19
COVID-19 Respiratory Infection · Acute Respiratory Disease
Primary: The Proportion of Patients With Acute Respiratory Viral Infections, Including COVID-19, at the End of the Prophylactic Period — 3; 13 participants
N/A N=218 Utilizing Text Messaging to Improve Vehicle Safety Among At-Risk Young Adults
Risk Reduction
Primary: Seat Belt Use — 34; 15 Participants
N/A N=63 The Inner Garden and Care for Children With Moderate to Severe Agitation
Child Behavior Disorders
Primary: Number of Crises — 97; 35 crises
Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
Phase 2 N=69 A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
Systemic Sclerosis
Primary: Mean Change From Baseline to Week 4 in the Number of Raynaud Attacks Per Week. — -3.41; -4.22 number of attacks — p=<0.05